Search

Your search keyword '"Kozloff, M. F."' showing total 26 results
Start Over Author "Kozloff, M. F."
26 results on '"Kozloff, M. F."'

3. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

Author

Kozloff, M F, primary, Martin, L P, additional, Krzakowski, M, additional, Samuel, T A, additional, Rado, T A, additional, Arriola, E, additional, De Castro Carpeño, J, additional, Herbst, R S, additional, Tarazi, J, additional, Kim, S, additional, Rosbrook, B, additional, Tortorici, M, additional, Olszanski, A J, additional, and Cohen, R B, additional

Published
2012
Full Text
View/download PDF

5. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS)

Author

Sugrue, M. M., primary, Purdie, D. M., additional, Feng, S., additional, Flynn, P. J., additional, Grothey, A., additional, Sargent, D. J., additional, Berlin, J. D., additional, Kabbinavar, F. F., additional, Dong, W., additional, and Kozloff, M. F., additional

Published
2008
Full Text
View/download PDF

7. Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC)

Author

Maitland, M. L., primary, Kasza, K. E., additional, Lacouture, M. E., additional, Liu, W., additional, Soltani, K., additional, Kozloff, M. F., additional, Hoffman, P. C., additional, Salgia, R., additional, Karrison, T., additional, and Vokes, E. E., additional

Published
2008
Full Text
View/download PDF

9. Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS)

Author

Flynn, P. J., primary, Sugrue, M. M., additional, Feng, S., additional, Purdie, D. M., additional, Grothey, A., additional, Sargent, D. J., additional, Berlin, J. D., additional, Kabbinavar, F. F., additional, Dong, W., additional, and Kozloff, M. F., additional

Published
2008
Full Text
View/download PDF

12. Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line

Author

Bekaii-Saab, T. S., primary, Bendell, J. C., additional, Cohn, A. L., additional, Kozloff, M. F., additional, Roach, N., additional, Sargent, D. J., additional, Tezcan, H., additional, Grothey, A., additional, Purdie, D. M., additional, and Sugrue, M. M., additional

Published
2008
Full Text
View/download PDF

22. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.

Author

Vokes EE, Haraf DJ, McEvilly JM, Mick R, Kozloff MF, Goldman MD, Moran WJ, Clendeninn NJ, Collier MA, and Weichselbaum RR

Subjects
Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Squamous Cell radiotherapy, Carcinoma, Squamous Cell surgery, Cisplatin administration & dosage, Combined Modality Therapy, Drug Administration Schedule, Drug Evaluation, Female, Fluorouracil administration & dosage, Head and Neck Neoplasms radiotherapy, Head and Neck Neoplasms surgery, Humans, Leucovorin administration & dosage, Male, Methotrexate administration & dosage, Middle Aged, Pyrimidines administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy
Abstract

To increase the complete remission (CR) rate achieved with two cycles of cisplatin, continuous infusion fluorouracil (5-FU) and oral leucovorin (PFL) we added two antifolate drugs, methotrexate (MTX) and the lipophilic piritrexim (PTX), to the combination (PFL-MP). Twenty-eight patients with previously untreated Stage IV squamous cell carcinoma of the head and neck received 2 cycles of cisplatin 100 mg/m2 on day 1 followed by a 5-day continuous infusion of 5-FU at 800 mg/m2/day and 100 mg of leucovorin administered orally every 4 hours. MTX was administered at 40 mg/m2 IV on day 15 and PTX at 75 mg orally twice daily on days 22 to 26, with cycle 2 starting on day 36. After 2 of the first 5 patients had tumor progression between days 15 and 35, the regimen was intensified to MTX 50 mg/m2, PTX 100 mg twice daily and a cycle duration of 28 days. Local therapy consisted of surgery and/or radiotherapy with concomitant 5-FU and hydroxyurea (FHX) administered every other week. Eleven patients (39%, 95% confidence intervals 21-57%) had a CR, 9 (32%) had a PR, and four patients had no response. Four patients were unevaluable for response to PFL-MP. Patients with poor performance status or N3 disease were less likely to achieve a CR. Mucositis following PFL was the dose-limiting toxicity. Local therapy included surgery in 15 patients and FHX chemoradiotherapy in 19 patients. The administration of FHX in this setting proved feasible and the regimen was given near the intended dose intensity in the majority of patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1992
Full Text
View/download PDF

23. Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study.

Author

Bitran JD, Kozloff MF, and Desser RK

Subjects
Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Female, Fluorouracil administration & dosage, Humans, Infusions, Intravenous, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Remission Induction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
Abstract

Twenty-four patients with refractory Stage IV breast cancer were treated with platinol (100 mg/m2 i.v. Day 1) and 5-fluorouracil (1000 mg/m2 as a continuous infusion over 24 h daily for 5 days). Objective responses occurred in 12 of 24 patients (50%). The median duration of response was 4.9 months. Platinol and 5-fluorouracil in combination are active agents in patients with refractory breast cancer, and clinical trials are warranted in previously untreated patients.

Published
1990
Full Text
View/download PDF

24. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM).

Author

Bitran JD, Desser RK, Kozloff MF, Billings AA, and Shapiro CM

Subjects
Adult, Aged, Clinical Trials as Topic, Doxorubicin administration & dosage, Drug Therapy, Combination, Female, Fluorouracil administration & dosage, Humans, Male, Middle Aged, Mitomycins administration & dosage, Remission, Spontaneous, Adenocarcinoma drug therapy, Antineoplastic Agents administration & dosage, Pancreatic Neoplasms drug therapy, Stomach Neoplasms drug therapy
Abstract

Twenty-six patients with metastatic pancreatic or gastric adenocarcinoma were treated with 5-fluorouracil, Adriamycin, and mitomycin C. One complete and five partial responses were observed among 15 patients with pancreatic adenocarcinoma (40% response rate) and six partial responses were observed among 11 patients with gastric adenocarcinoma (55% response rate). Responders had a significantly longer survival than nonresponders in both groups.

Published
1979

25. Melphalan, vincristine, and 5-FU in advanced colonic carcinoma: results of a pilot study.

Author

Ashenhurst J, Bitran JD, Robin E, Desser RK, Shapiro C, Kozloff MF, and Billings AA

Subjects
Aged, Carcinoembryonic Antigen analysis, Colonic Neoplasms immunology, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Probability, Prognosis, Colonic Neoplasms drug therapy, Fluorouracil administration & dosage, Melphalan administration & dosage, Vincristine administration & dosage
Abstract

The results of treatment with melphalan, vincristine, and 5-FU (MVF) in 32 patients with advanced colonic carcinoma are reported. The objective response rate among 31 patients with measurable disease was 16% (five patients responded). The projected survival for all 32 patients was 277 days. Patients with objective response to MVF had a projected survival of 314 days, significantly longer than the survival of patients with no response to therapy, 84 days (P = 0.01). While toxic effects were mild with MVF, this regimen appears to have greater activity in advanced colonic carcinoma than therapy with 5-FU alone or in combination with nitrosoureas.

Published
1981

26. Intracavitary bleomycin for the control of malignant effusions.

Author

Bitran JD, Brown C, Desser RK, Kozloff MF, Shapiro C, and Billings AA

Subjects
Adult, Aged, Bleomycin adverse effects, Female, Fever chemically induced, Humans, Male, Middle Aged, Pleural Effusion drug therapy, Ascites, Bleomycin administration & dosage, Peritoneal Neoplasms drug therapy, Pleural Neoplasms drug therapy
Abstract

The results of treatment with intracavitary bleomycin are reported in twenty patients with a malignant pleural effusion and five patients with malignant ascites. The control rate was 17/20 (85%) patients with malignant pleural effusions and 3/5 (60%) patients with malignant ascites. Toxicities were minimal with fever being the most common side effect in four patients (16%. Bleomycin is an effective and nontoxic sclerosing agent.

Published
1981
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results